» Articles » PMID: 15094768

EIF-4E Expression and Its Role in Malignancies and Metastases

Overview
Journal Oncogene
Date 2004 Apr 20
PMID 15094768
Citations 338
Authors
Affiliations
Soon will be listed here.
Abstract

The contribution of the mRNA cap-binding protein, eIF-4E, to malignant transformation and progression has been illuminated over the past decade. eIF-4E overexpression has been demonstrated in human tumors of the breast, head and neck, colon, prostate, bladder, cervix and lung, and has been related to disease progression. Overexpression of eIF-4E in experimental models dramatically alters cellular morphology, enhances proliferation and induces cellular transformation, tumorigenesis and metastasis. Conversely, blocking eIF-4E function by expression of antisense RNA, or overexpression of the inhibitory eIF-4E binding proteins (4E-BPs), suppresses cellular transformation, tumor growth, tumor invasiveness and metastasis. Although eIF-4E regulates the recruitment of mRNA to ribosomes, and thereby globally regulates cap-dependent protein synthesis, eIF-4E contributes to malignancy by selectively enabling the translation of a limited pool of mRNAs--those that generally encode key proteins involved in cellular growth, angiogenesis, survival and malignancy (e.g. cyclin D1, c-myc, vascular endothelial growth factor, matrix metalloprotease 9). A deeper understanding of the role of eIF-4E in regulating the translation of the diverse gene products involved in all aspects of malignancy will improve the capacity to exploit eIF-4E as a therapeutic target and as a marker for human cancer progression.

Citing Articles

Sortase-Mediated Fluorescent Labeling of eIF4E for Investigating Translation Initiation Mechanisms.

Pi J, Joseph S Biochemistry. 2025; 64(5):1099-1108.

PMID: 39968718 PMC: 11887568. DOI: 10.1021/acs.biochem.4c00851.


Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells.

Lum M, Jonas K, Parmar S, Black A, OConnor C, Dobersch S J Clin Invest. 2025; 135(4).

PMID: 39869680 PMC: 11827888. DOI: 10.1172/JCI176093.


Oncogenic accumulation of cysteine promotes cancer cell proliferation by regulating the translation of D-type cyclins.

Okano Y, Yamauchi T, Fukuzaki R, Tsuruta A, Yoshida Y, Tsurudome Y J Biol Chem. 2024; 300(11):107890.

PMID: 39413876 PMC: 11650723. DOI: 10.1016/j.jbc.2024.107890.


Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets.

Sehrawat U Int J Mol Sci. 2024; 25(19).

PMID: 39409166 PMC: 11477148. DOI: 10.3390/ijms251910835.


MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptation.

Bordone R, Ivy D, DAmico R, Barba M, Gaggianesi M, Di Pastena F Oncogene. 2024; 43(46):3349-3365.

PMID: 39306615 DOI: 10.1038/s41388-024-03170-6.